News

Omni Bio is involved in developing alternative uses of Alpha-1 antitrypsin (AAT), designed for treating various indications, as well as recombinant forms of AAT. Prior to joining the

Solithromycin, the company’s fluoroketolide antibiotic candidate, is designed for treating patients with community-acquired bacterial pneumonia (CABP). The study, which will enroll approximately 800 patients with PORT-II to PORT-IV

HPA seasonal flu surveillance head Richard Pebody said HPA is seeing an increase in flu activity mainly among school children indicating the start of this year’s flu season.

To manage the rising number of pertussis cases, Synthetic Biologics intends to decrease the mortality rate in infants as well as to decrease the chronic cough in adults

Meningitec is an established commercial vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup C. Nuron will also use the funds for clinical development of its new

In early 2012, Dendreon had decided to bring down Provenge production at the facility as part of its strategic restructuring plan to increase profitability and future growth. Dendreon

BIGHEALTHr solution, which comes with built-in ontologies, can be configured to collect big data from social media, videos, scholar publications, clinical trials, FDA, Wikipedia, mobile apps, product reviews,

As part of the alliance, the companies will conduct data-driven collaborative research to leverage Humedica’s experience to gather and normalise de-identified healthcare data from disparate systems and Pfizer’s

The multi-center Trial 290-005 is designed to assess MGCD290 in combination with fluconazole against only fluconazole in vulvovaginal candidiasis (VVC) patients. MethylGene president and chief executive officer Dr.